Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia.

Cather C, Dyer MA, Burrell HA, Hoeppner B, Goff DC, Evins AE.

J Dual Diagn. 2013;9(1):87-93.

2.

A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.

Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC.

J Clin Psychopharmacol. 2007 Aug;27(4):380-6.

PMID:
17632223
3.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
4.

Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention.

Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, Rowland KM, Bernath A, Loots ML, Le-Lindqwister NA, Tschetter LK, Garneau SC, Flynn KA, Ebbert LP, Wender DB, Loprinzi CL.

Mayo Clin Proc. 2007 Feb;82(2):186-95.

PMID:
17290726
5.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.

PMID:
21328282
6.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006103.

PMID:
21154363
7.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103. doi: 10.1002/14651858.CD006103.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(12):CD006103.

PMID:
18646137
8.

Interventions for smoking cessation and reduction in individuals with schizophrenia.

Tsoi DT, Porwal M, Webster AC.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD007253. doi: 10.1002/14651858.CD007253.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;2:CD007253.

PMID:
20556777
9.

Nicotine replacement therapy for smoking cessation.

Silagy C, Mant D, Fowler G, Lancaster T.

Cochrane Database Syst Rev. 2000;(3):CD000146. Review. Update in: Cochrane Database Syst Rev. 2001;(3):CD000146.

PMID:
10908462
10.

Relapse prevention interventions for smoking cessation.

Hajek P, Stead LF, West R, Jarvis M, Lancaster T.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003999. doi: 10.1002/14651858.CD003999.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;8:CD003999.

PMID:
19160228
11.

A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse.

Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, Petkova E, Rodriguez K.

Addiction. 2007 Aug;102(8):1292-302.

PMID:
17624979
12.

A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia.

George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, Creeden CL, Potenza MN, Feingold A, Jatlow PI.

Biol Psychiatry. 2008 Jun 1;63(11):1092-6. Epub 2007 Dec 21.

13.

Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction.

Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ, Schroeder JR.

Pediatrics. 2005 Apr;115(4):e407-14.

PMID:
15805342
14.

Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD.

Ann Intern Med. 2001 Sep 18;135(6):423-33.

PMID:
11560455
15.

Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking.

Walker N, Howe C, Bullen C, McRobbie H, Glover M, Parag V, Williman J, Veale R, Nosa V, Barnes J.

BMC Public Health. 2011 Nov 21;11:880. doi: 10.1186/1471-2458-11-880.

16.

Nicotine replacement therapy for smoking cessation.

Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD000146. doi: 10.1002/14651858.CD000146.pub4. Review.

PMID:
23152200
17.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006103. Review. Update in: Cochrane Database Syst Rev. 2008;(3):CD006103.

PMID:
17253581
18.

A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females.

Evins AE, Pachas G, Mischoulon D, Urbanoski K, Carlini S, Sousa J, Bentley K, Rigotti NA, Nino-Gomez J, Loebl T, Janes AC, Kaufman MJ, Fava M.

J Clin Psychopharmacol. 2011 Oct;31(5):597-602. doi: 10.1097/JCP.0b013e31822bb390.

19.
20.

A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics.

Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA.

Nicotine Tob Res. 2009 Jul;11(7):859-67. doi: 10.1093/ntr/ntp077. Epub 2009 May 29.

Items per page

Supplemental Content

Write to the Help Desk